GlassScriptPhysician profile
Bindu Sudhakaran
NPI 1154379709
$7,042.29
in general payments reported to CMS, 2019-2025
33 companies · $1,823 in 2025
The $1,823 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,273 · 2020: $204 · 2021: $255 · 2022: $690 · 2023: $1,142 · 2024: $1,654 · 2025: $1,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,619.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,745.89 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,281.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $526.22 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $450.12 | 2023-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $440.75 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Dexcom, INC. | $281.37 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Medtronic, INC. | $239.34 | 2024-2025 | Interstim, Signia |
| Amarin Pharma, INC. | $227.69 | 2019-2022 | |
| Exact Sciences Corporation | $185.48 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $154.37 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $148.75 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.61 | 2019-2025 | Jardiance |
| Abbott Laboratories | $125.93 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $120.04 | 2022-2025 | |
| Astellas Pharma US INC | $103.15 | 2019-2023 | Myrbetriq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $86.60 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $76.24 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.28 | 2020 | |
| Merck Sharp & Dohme LLC | $66.80 | 2019-2025 | Gardasil 9, Capvaxive |
| Sanofi Pasteur INC. | $66.31 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $63.85 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $59.53 | 2023-2025 | Quviviq, Quviviq |
| Dynavax Technologies Corporation | $59.29 | 2024-2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $54.62 | 2019-2022 | |
| Inspire Medical Systems, INC. | $45.96 | 2025 | Inspire |
| Corcept Therapeutics | $39.74 | 2025 | Korlym |
| Phadia US INC. | $35.13 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.88 | 2022-2024 | Trulance, Xifaxan |
| Kyowa Kirin, INC. | $29.24 | 2025 | |
| Axsome Therapeutics, INC. | $19.99 | 2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $19.37 | 2023 | Gattex |
| Janssen Pharmaceuticals, INC | $17.06 | 2019 | |
| Esperion Therapeutics, INC. | $15.70 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindu Sudhakaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.